On 24 July, IFPMA made a statement at the fourth meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva.
Read moreOn 24 July, IFPMA delivered a statement for agenda item 3 at the “Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) to draft and negotiate a WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response and the Working Group on Amendments to the International Health Regulations (WGIHR) (2005)” in Geneva.
Read moreOn 21 July, IFPMA delivered a statement for agenda item 2 at the “Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) to draft and negotiate a WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response and the Working Group on Amendments to the International Health Regulations (WGIHR) (2005)” in Geneva.
Read moreOn 20 July 2023, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a virtual workshop on the development of a global Pharmaceutical Quality Knowledge Management System (PQ KMS), which aims to facilitate the exchange of knowledge related to pharmaceutical quality amongst national regulatory authorities worldwide.
Read morePharmaceutical innovation is a remarkable force that propels scientific knowledge forward and advances societal progress. As we approach Youth World Skills Day on 15 July, it is an opportunity to reflect on the need to invest in young innovators who can carry the industry’s innovation story forward. Our active involvement contributes to a thriving innovation...
Read more
The COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Sérgio Cavalheiro Filho explains what we can learn from this experience when it comes to quality and supply of medicinal products.
Read more
CEOs from Pfizer, Roche, and Daiichi Sankyo take up roles on IFPMA CEO leadership team The global biopharmaceutical industry trade body, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), has announced a new line up for their CEO leadership team for the coming two years. The CEOs who will provide strategic guidance to the...
Read moreThe COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Sarah Adam explains what we can learn from this experience when it comes to clinical trials.
Read more
This blog was originally published on 28 June by Media Planet in Global Cause and as a supplement to The Guardian. There is a huge gap in cancer mortality rates between high and lower-resource settings, with 70% of global cancer deaths occurring in low- and middle-income countries (LMICs). The gap in cancer mortality rates is...
Read more
Artificial intelligence; machine learning; real-world data; generative biology. What do these popular phrases mean for clinical trial innovation? They mean the potential for greater understanding of diseases; better and more rapid execution of trials; more breakthrough medicines for patients. Fast-moving technological innovations can also cause uncertainty. To fully leverage these opportunities, we need all...
Read more
On 22 June, IFPMA delivered a statement at the Human Rights Council (HRC) 53 Regular Session: Interactive dialogue on the right to health.
Read moreAcross the globe, people often associate tuberculosis (TB) with rows of beds in archaic sanitoriums. But this is not a disease of the past, it remains one of the world’s most deadly public health challenges and one our industry is determined to remedy. Following the COVID-19 pandemic, TB is once again the world’s leading cause...
Read more